Enovis Corporation: Q2 2022 Form 10-Q Summary
Business context and reporting period
Enovis Corporation, formerly Colfax Corporation, reported results for the quarter and six months ended July 1, 2022. On April 4, 2022, the company completed the tax-free separation of its fabrication technology business into ESAB Corporation and retained 10% of ESAB. The former fabrication technology business is presented as discontinued operations for all periods. Enovis now operates through Prevention and Recovery and Reconstructive segments and began trading under the ticker ENOV on April 5, 2022.
Key financial metrics
| Metric | Three months ended July 1, 2022 | Three months ended July 2, 2021 | Six months ended July 1, 2022 | Six months ended July 2, 2021 |
|---|---|---|---|---|
| Net sales | $395.1 million | $356.1 million | $770.6 million | $667.2 million |
| Gross profit | $215.9 million | $200.6 million | $421.8 million | $371.9 million |
| Gross margin | 54.6% | 56.3% | 54.7% | 55.7% |
| Operating income (loss) | $5.6 million | $(10.4) million | $(25.1) million | $(28.5) million |
| Net income attributable to Enovis | $76.9 million | $28.6 million | $91.9 million | $47.7 million |
| Adjusted EBITDA | $56.2 million | $50.6 million | $103.9 million | $87.9 million |
| Adjusted EBITDA margin | 14.2% | 14.2% | 13.5% | 13.2% |
| Diluted EPS, consolidated operations | $1.41 | $0.56 | $1.69 | $0.98 |
Continuing-operations net income was $120.7 million in the second quarter and $82.6 million for the six-month period, compared with losses of $42.1 million and $74.0 million, respectively, in the prior-year periods. Results benefited substantially from a $135.5 million unrealized gain on the retained ESAB investment and a $33.0 million insurance settlement gain. These items are unusual and should not be viewed as recurring operating performance.
Prevention and Recovery sales were $263.8 million in the quarter and $508.6 million year to date. Reconstructive sales were $131.3 million and $262.0 million, respectively. Reconstructive sales growth was driven principally by acquisitions and organic growth, while Prevention and Recovery quarterly sales declined 1% because of foreign exchange headwinds and fewer selling days.
Cash flow, liquidity, debt, and balance sheet
- Cash and cash equivalents were $95.6 million at July 1, 2022, compared with $680.3 million at December 31, 2021. The comparison is affected by the ESAB separation and reclassification of discontinued operations.
- Six-month operating cash flow was an outflow of $39.3 million, compared with $162.8 million of cash provided in the prior-year period. Working-capital investment, including higher inventories, was a major use of cash.
- Investing cash flow was an outflow of $80.2 million, including $47.8 million of capital expenditures and $35.1 million for acquisitions and investments.
- Financing cash flow was an outflow of $506.3 million. The company received a $1.2 billion distribution from ESAB and used proceeds, new term-loan borrowings, and cash on hand to retire substantially more debt.
- Total debt was $449.5 million at July 1, 2022, consisting primarily of the Enovis term loan. The prior-year-end total was $2.1 billion. The term loan had an April 2023 maturity date; the $900 million revolving facility matures in April 2027.
- The revolving facility had $900 million of availability, and the weighted-average interest rate on Enovis Credit Agreement borrowings was 2.58% at July 1, 2022. The company stated that it was in compliance with credit covenants and believed liquidity was adequate for the next twelve months.
- Inventory increased to $400.9 million from $356.2 million at December 31, 2021, partly to mitigate supply-chain volatility.
Material changes versus the prior comparable period
- Net sales increased 10.9% in the second quarter and 15.5% for the six-month period. Six-month growth comprised 5.1% existing-business growth, 12.4% acquisition contribution, and a 2.0% foreign-exchange reduction.
- Gross margins declined 170 basis points in the quarter and 100 basis points year to date because supply-chain, logistics, inventory step-up, and other inflationary costs exceeded pricing benefits.
- Adjusted EBITDA increased 11% in the quarter and 18% year to date. The quarterly margin was unchanged, while the six-month margin improved 30 basis points.
- Strategic transaction costs increased to $12.7 million in the quarter and $24.4 million year to date, primarily due to the ESAB separation and acquisition integration.
- Interest expense declined to $4.5 million in the quarter and $11.6 million year to date as debt was reduced. Debt extinguishment charges were $20.1 million in 2022 compared with $29.9 million in the second quarter of 2021.
- The six-month discontinued-operations contribution fell to $10.7 million from $123.9 million, reflecting the separation of the fabrication technology business and separation-related costs.
Guidance, outlook, commentary, and risks
The filing does not provide explicit quantitative revenue or earnings guidance. Management expects the retained ESAB shares to be divested in a tax-efficient exchange for outstanding debt no later than 12 months after the separation date. Management expects recent Reconstructive acquisitions, which were dilutive to current margins, to become accretive in future years.
Management identified continuing pressure from COVID-19 disruptions, elective-procedure delays, supply-chain constraints, labor shortages, logistics delays, inflation in materials and freight, foreign-exchange volatility, and the Russia-Ukraine conflict. Other risks include acquisition integration, medical-device regulatory compliance, product liability, intellectual-property protection, cybersecurity, impairment of goodwill and intangibles, tax matters, credit-facility restrictions, and potential separation-related indemnification or tax liabilities.
Pending legal proceedings arise in the ordinary course of business and were not expected by management to have a material adverse effect, although ultimate outcomes cannot be assured. The company reported effective disclosure controls and no material changes to internal control over financial reporting.
Important facts for investors to verify
- Separate recurring operating performance from the $135.5 million ESAB fair-value gain and $33.0 million insurance settlement gain.
- Track operating cash conversion, inventory levels, and working-capital requirements after the separation.
- Verify the timing and tax-efficient execution of the planned ESAB stake divestiture and intended debt reduction.
- Monitor the April 2023 term-loan maturity, variable-rate exposure, covenant thresholds, and available revolver capacity.
- Assess whether supply-chain inflation, foreign-exchange pressure, and elective-procedure delays continue to affect gross margins.
- Evaluate acquisition integration, purchase-price accounting, contingent consideration of approximately $25 million, and the path to margin accretion in Reconstructive.